California Public Employees Retirement System Has $2.51 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

California Public Employees Retirement System trimmed its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 26.0% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 40,302 shares of the company's stock after selling 14,145 shares during the period. California Public Employees Retirement System owned approximately 0.12% of TransMedics Group worth $2,513,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Captrust Financial Advisors boosted its stake in TransMedics Group by 20.6% during the third quarter. Captrust Financial Advisors now owns 1,988 shares of the company's stock worth $312,000 after buying an additional 340 shares during the period. Janus Henderson Group PLC boosted its stake in shares of TransMedics Group by 10.2% in the third quarter. Janus Henderson Group PLC now owns 15,463 shares of the company's stock valued at $2,426,000 after purchasing an additional 1,428 shares during the period. Quarry LP grew its holdings in shares of TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company's stock valued at $58,000 after purchasing an additional 312 shares in the last quarter. National Bank of Canada FI increased its stake in TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company's stock worth $65,000 after buying an additional 262 shares during the period. Finally, Zacks Investment Management acquired a new stake in TransMedics Group during the 3rd quarter worth approximately $1,607,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Remove Ads

TransMedics Group Price Performance

Shares of TMDX stock traded up $2.28 during midday trading on Monday, reaching $82.86. 185,164 shares of the company were exchanged, compared to its average volume of 1,651,956. The company's 50 day moving average price is $70.94 and its two-hundred day moving average price is $81.18. The company has a market cap of $2.79 billion, a P/E ratio of 88.14 and a beta of 2.14. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. JPMorgan Chase & Co. restated a "neutral" rating and issued a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Wednesday, March 26th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, TransMedics Group has a consensus rating of "Moderate Buy" and a consensus target price of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.